Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A two part study evaluating single and multiple ascending dose of Asp8062 to assess its safety, tolerability, and pharmacokinetic profile in healthy subjects

Trial Profile

A two part study evaluating single and multiple ascending dose of Asp8062 to assess its safety, tolerability, and pharmacokinetic profile in healthy subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Sep 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ASP 8062 (Primary)
  • Indications Fibromyalgia
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 16 Sep 2018 Results assessing Safety, Tolerability, Pharmacokinetic Profile, and Pharmacodynamic Effects of ASP8062 in three phase I studies (n=108) presented at the 17th World Congress on Pain
    • 27 Mar 2018 New trial record
    • 24 Mar 2018 Results from two phase I studies assessing safety and pharmacokinetic profile of ASP8062 after single or multiple doses presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top